Research programme: neurological disorder therapeutics - 4SC Discovery/CRELUX/UCB
Latest Information Update: 16 Jul 2016
At a glance
- Originator 4SC Discovery; CRELUX; UCB
- Developer 4SC Discovery; CRELUX
- Class Small molecules
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Neurological-disorders in Germany
- 15 Apr 2016 CRELUX has been acquired by WuXi AppTec
- 11 Jun 2013 Early research in Neurological disorders in Germany (unspecified route)